A phase 1 clinical trial published in 2026 evaluated BBM-P002, an investigational gene therapy for Parkinson disease. Which ...
A target trial emulation pooling ACCORD-BP and SPRINT data found calcium channel blocker regimens reduced blood pressure variability without changing cardiovascular outcomes.
The FDA has accepted the resubmitted new drug application (NDA) for troriluzole (Vyglxia; Biohaven) for the treatment of ...
Remibrutinib (Novartis), an oral Bruton tyrosine kinase (BTK) inhibitor, reduced annualized relapse rate (ARR) vs ...
One-year data from the phase 3 AQUARELLE study show that divozilimab (Biocad), an anti-CD20 monoclonal antibody, reduced ...
A pooled analysis of 4 randomized trials found that more time with blood pressure below 130 mmHg after intracerebral ...
A professor at Polytechnique Montreal discussed advances in brain and spinal cord MRI for multiple sclerosis, including ...
FcRn inhibition targets the persistence of pathogenic IgG rather than its production. The panel explains why this downstream ...
Decade of OPERA Data Supports Early Ocrelizumab Treatment Initiation in Relapsing Multiple Sclerosis
A newly published study showed that patients with relapsing multiple sclerosis (RMS) who started ocrelizumab (Ocrevus; ...
A four-year-old with regression, ptosis, and feeding problems illustrates the textbook features of severe early-onset TK2D ...
This episode, titled ‘Understanding MG Pathophysiology and Therapeutic Targets,’ features panelists examining how advances in ...
The phase 2 FENerations1 study is an open-label, single-arm, small-scale study evaluating fenebrutinib dosing in 8 to 12 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results